Today: 8 June 2026
Browse Category

Biotechnology 2 February 2026 - 2 March 2026

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals shares fell 2.9% to $8.50 premarket Monday after new clinical data on its hereditary angioedema drug pipeline. Interim results from the ALPHA-SOLAR study showed navenibart reduced mean monthly HAE attacks by 91% among 29 patients, with one discontinuation due to cancer. The company reaffirmed 2026 revenue guidance for ORLADEYO and expects a Phase 3 navenibart filing by late 2027.
2 March 2026
·
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares traded near $0.42 in early premarket Tuesday after plunging about 80% when its main drug failed to meet the primary goal in a Phase 3 trial. The company said the study’s key endpoint improved by 13.3 meters but did not reach statistical significance. Analysts downgraded the stock and flagged risks around funding and regulatory timelines. Gossamer plans to meet the FDA and paused another study.
24 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL shares plunged nearly 50% to $51.00 after a UK trial showed its Galleri blood test missed the main goal of significantly improving early cancer detection. The study’s results complicate prospects for broad screening and reimbursement. Focus now shifts to U.S. regulators and Medicare-linked evidence. GRAIL reported Q4 revenue up 14% to $43.6 million and said its FDA approval submission is under review.
20 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche said its experimental MS drug fenebrutinib met the main goal in a late-stage study for primary progressive multiple sclerosis, showing “non-inferiority” to Ocrevus but with more frequent, reversible liver enzyme elevations and a higher share of fatal cases. Roche shares last closed down 0.6% at 356.40 francs. Investors await Monday’s webcast for more data and filing plans.
8 February 2026
····
Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly shares climbed 3.7% in after-hours trading after the FDA announced plans to restrict GLP-1 ingredients in unapproved compounded drugs. Hims & Hers shares dropped nearly 12% after being referred for a Justice Department probe. Investors are watching for details on enforcement and pricing pressure as the market reacts to moves against copycat obesity drugs.
7 February 2026
···
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina shares dropped 10.3% to $119.91 after the company forecast 2026 revenue of $4.5–$4.6 billion and non-GAAP EPS of $5.05–$5.20. Management cited progress in China but said approvals are still needed for instrument sales. Fourth-quarter revenue rose 5% to $1.16 billion, with ex-China revenue up 8%. The company expects 2026 organic revenue growth of 2–4% excluding China.
6 February 2026
···
Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher shares rose 0.6% to $545.58 Friday afternoon, recovering some ground after a 4% drop Thursday. The move lagged the broader market, with the S&P 500 up 1.73%. Investors remain cautious amid weak academic research funding and uncertain lab order trends. Upcoming U.S. jobs and inflation data could affect rate expectations and valuations.
6 February 2026
··
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics shares surged nearly 19% Thursday after the company filed an amended IND application for a Phase 2a trial of TTX-MC138 in colorectal cancer patients. Trading volume hit 11.5 million shares, up from 8,500 the previous day. The dose-expansion study, set to begin in early 2026, will enroll up to 45 patients with positive ctDNA markers. The trial will run with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform.
5 February 2026
·
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
···
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience shares surged 14% to $46.88 Monday after posting record Q1 revenue of $103.7 million and raising its full-year forecast. Gross margin reached 52%, with net loss narrowing to $30.5 million. The company reaffirmed its target to reach adjusted EBITDA breakeven by late fiscal 2026. Investors are watching if Twist can sustain margins and meet its March-quarter revenue guidance.
2 February 2026
···
1 2 3 4 5 … 18

Stock Market Today

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop